RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Vera gone??..Rumpl3StiltSkin wrote: CancerSlayer wrote:
stocksnbonds458 wrote: With all due respect Enrique, in her own words she was there to bring this to commercialization. Per Vera: "I feel my extensive global experience in clinical research and quality assurance will support the Companys primary objective of successfully developing with the objective of commercializing its Anti-Cancer Therapy (ACT) technology". At the very least, IMHO, the shareholders deserve an explanation of her departure and not just a quickie one liner couched within a parapraph in the recent update. Theralase is not treating its shareholders with respect here.
In addition to cost savings, considering our new fully equipped research center (effective 4/2022) & recent association with LKSKI, I imagine there was also a fair degree of duplication/overlap in expertise with respect to clinical trial guidance & commercialization. Nonetheless, I feel confident TLT benefited from whatever additional info/value she was able to provide (in conjunction with LKSKI) during her limited employment...planned or unplanned. JMO.
Well, it can't just be me? Isn't this NR the first time in this Phase 2 where no one was confused by the CR data?? I think we've all been very correctly assesing what this group of numbers has been telling us... :-) Maybe Dr. Rad did do her work afterall...??
"no one was confused..." Well, almost right Rumpl...I have this tendency at times to not only confuse myself, but also others in the process. Used to be good at this stuff but father time has kicked in. My apologies to all. Be best to just wait for that elusive BTD ; )...GLTA.